Floatz logo

Car-Bcma T Cells

Refractory or Relapsed Multiple Myeloma

CARsgen Therapeutics Co., Ltd.Cell therapyPhase 1/2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

498 Active assets in the Refractory or Relapsed Multiple Myeloma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB

View all 50 →

Same molecule, other indications

Car-Bcma T Cells is also rated in:

B-cell non-Hodgkin lymphomaDormant
D
Indicative ·
30 / 100
View asset →
B Cell LeukemiaDormant
D
Indicative ·
30 / 100
View asset →
exocrine pancreatic carcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →